Elise Margaretha Adriana Slob

Dr. Elise Margaretha Adriana Slob

Clinical pharmacology and toxicology, Leiden University Medical Center, Leiden, The Netherlands
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2018 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
ZZZulfan Zazuli
Zulfan Zazuli
SVSusanne J.H. Vijverberg
Susanne J.H. Vijverberg
ESElise Margaretha Adriana Slob
Elise Margaretha Adriana Slob
GLGeoffrey Liu
Geoffrey Liu
BCBruce Carleton
Bruce Carleton
Anke H. Maitland-van der ZeeAnke H. Maitland-van der Zee
Anke H. Maitland-van der Zee
Background: Nephrotoxicity is a notable adverse effect in cisplatin treated patients characterized by tubular injury and/or increased serum creatinine (SCr) with incidence varying from 20 to 70%. Pharmacogenomics has been shown to identify strongly predictive genetic markers to help determine which patients are more likely to experience, for example, a serious adverse drug reaction or receive optimal benefit through enhanced efficacy. Genetic variations have been reported to influence the risk of cisplatin nephrotoxicity; however, a comprehensive overview is lacking. Methods: A systematic review was performed using Pubmed, Embase and Web of Science on clinical studies that used cisplatin-based chemotherapy as treatment, had available genotyping data, and evaluated nephrotoxicity as an outcome. The quality of reporting was assessed using the STrengthening the REporting of Genetic Association Studies (STREGA) checklist. Results: Twenty-eight eligible studies were included; all were candidate gene studies. Over 300 SNPs across 135 genes were studied; 29 SNPs in 14 genes were significantly associated with cisplatin-induced nephrotoxicity. A variation in SLC22A2 rs316019, a gene involved in platinum uptake by the kidney, was associated with different measures of nephrotoxicity in four independent studies. Further, variants of ERCC1 (rs11615 and rs3212986) and ERCC2 (rs13181), two genes involved in DNA repair, were found to be positively associated with increased risks of nephrotoxicity in two independent studies. Conclusion: Three genes consistently associated with cisplatin-induced nephrotoxicity. Further research is needed to assess the biological mechanism and the clinical value of modifying treatment based on SLCC22A2 and ERCC1/2 genotypes.

5 March 2020 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
ESElise Margaretha Adriana Slob
Elise Margaretha Adriana Slob
BBBronwyn Brew
Bronwyn Brew
SVSusanne J.H. Vijverberg
Susanne J.H. Vijverberg
CKChantal J.A.R. Kats
Chantal J.A.R. Kats
CLCristina Longo
Cristina Longo
Anke H. Maitland-van der ZeeAnke H. Maitland-van der Zee
Anke H. Maitland-van der Zee
Rationale: Early-life antibiotic use has been associated with the development of atopic diseases, but the aetiology remains unclear. To elucidate the aetiology, we used a discordant twin design to control for genetic and environmental confounding.Methods: We conducted a retrospective cohort study in twins aged 3–10 years from the Netherlands Twin Register (NTR, n=35 365) and a replication study in twins aged 9 years from the Childhood and Adolescent Twin Study in Sweden (CATSS, n=7916). Antibiotic use was recorded at age 0–2 years. Doctor-diagnosed asthma and eczema were reported by parents when children were aged 3–12 years in both cohorts. Individuals were included in unmatched analyses and in co-twin control analyses with disease discordant twin pairs.Results: Early-life antibiotic use was associated with increased risk of asthma (NTR OR 1.34, 95% CI 1.28–1.41; CATSS OR 1.45, 95% CI 1.34–1.56) and eczema (NTR OR 1.08, 95% CI 1.03–1.13; CATSS OR 1.07, 95% CI 1.01–1.14) in unmatched analyses. Co-twin analyses in monozygotic and dizygotic twin pairs showed similar results for asthma (NTR OR 1.54, 95% CI 1.20–1.98; CATSS OR 2.00, 95% CI 1.28–3.13), but opposing results for eczema in the NTR (OR 0.99, 95% CI 0.80–1.25) and the CATSS (OR 1.67, 95% CI 1.12–2.49). The risk of asthma increased for antibiotics prescribed for respiratory infections (CATSS OR 1.45, 95% CI 1.34–1.56), but not for antibiotics commonly used for urinary tract/skin infections (CATSS OR 1.02, 95% CI 0.88–1.17).Conclusion: Children exposed to early-life antibiotic use, particularly prescribed for respiratory infections, may be at higher risk of asthma. This risk can still be observed when correcting for genetic and environmental factors. Our results could not elucidate whether the relationship between early-life antibiotic use and eczema is confounded by familial and genetic factors.

10 July 2018 in Pediatric Allergy and Immunology
Verified
Journal Article
Closed access
PDF file
ESElise Margaretha Adriana Slob
Elise Margaretha Adriana Slob
SVSusanne J.H. Vijverberg
Susanne J.H. Vijverberg
CPColin N. A. Palmer
Colin N. A. Palmer
ZZZulfan Zazuli
Zulfan Zazuli
NFNiloufar Farzan
Niloufar Farzan
Anke H. Maitland-van der ZeeAnke H. Maitland-van der Zee
Anke H. Maitland-van der Zee

12 November 2020 in International Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
ESElise Margaretha Adriana Slob
Elise Margaretha Adriana Slob
BBBronwyn K Brew
Bronwyn K Brew
SVSusanne J H Vijverberg
Susanne J H Vijverberg
TDTalitha Dijs
Talitha Dijs
CBCatharina E M van Beijsterveldt
Catharina E M van Beijsterveldt
DBDorret I Boomsma
Dorret I Boomsma
Background: Development of the gut-brain axis in early life may be disturbed by antibiotic use. It has been hypothesized that this disturbance may contribute to development of neurodevelopmental disorders, including autism spectrum disorder and attention-deficit hyperactivity disorder. We aimed to assess the association between antibiotic use in early life and the risk of developing attention-deficit hyperactivity disorder or autism spectrum disorder, while controlling for shared genetic and environmental factors in a discordant twin design. Methods: We conducted a cohort study in twins (7–12 years; 25 781 twins) from the Netherlands Twin Register (NTR) and a replication study in the Childhood and Adolescent Twin Study in Sweden (CATSS; 7946 9-year-old twins). Antibiotic use was recorded before age 2 years. Attention-deficit hyperactivity disorder and autism spectrum disorder were parent-reported in the Netherlands Twin Register and register-based in the Childhood and Adolescent Twin Study in Sweden. Results: Early-life antibiotic use was associated with increased risk of attention-deficit hyperactivity disorder development [pooled odds ratio (OR) 1.10, 95% confidence interval (CI) 1.02-1.17] and autism spectrum disorder (pooled OR 1.15, 95% CI 1.06-1.25) in a case-control design. When restricting to monozygotic twin pairs discordant for the outcome, associations disappeared for both disorders in both cohorts (attention-deficit hyperactivity disorder OR 0.90, 95% CI 0.48-1.69 and OR 0.80, 95% CI 0.37-1.76, and autism spectrum disorder OR 0.66, 95% CI 0.38-1.16 and OR 0.29, 95% CI 0.02-4.50, respectively). Conclusions: Our findings suggest that the association between early-life antibiotic use and risk of attention-deficit hyperactivity and autism spectrum disorder may be confounded by shared familial environment and genetics.

21 November 2017 in Expert Review of Respiratory Medicine
Verified
Journal Article
Open access
SVSusanne J.H. Vijverberg
Susanne J.H. Vijverberg
NFNiloufar Farzan
Niloufar Farzan
ESElise Margaretha Adriana Slob
Elise Margaretha Adriana Slob
ANAnne H. Neerincx
Anne H. Neerincx
Anke H. Maitland-van der ZeeAnke H. Maitland-van der Zee
Anke H. Maitland-van der Zee
Introduction: Asthmatic patients show a large heterogeneity in response to asthma medication. Rapidly evolving genotyping technologies have led to the identification of various genetic variants associated with treatment outcomes. Areas covered: This review focuses on the current knowledge of genetic variants influencing treatment response to the most commonly used asthma medicines: short- and long-acting beta-2 agonists (SABA/LABA), inhaled corticosteroids (ICS) and leukotriene modifiers. This review shows that various genetic variants have been identified, but none are currently used to guide asthma treatment. One of the most promising genetic variants is the Arg16 variant in the ADRB2 gene to guide LABA treatment in asthmatic children. Expert commentary: Poor replication of initially promising results and the low fraction of variability accounted for by single genetic variants inhibit pharmacogenetic findings to reach the asthma clinic. Nevertheless, the identification of genetic variation influencing treatment response does provide more insights in the complex processes underlying response and might identify novel targets for treatment. There is a need to report measures of clinical validity, to perform precision-medicine guided trials, as well as to understand how genetic variation interacts with environmental factors. In addition, systems biology approaches might be able to show a more complete picture of these complex interactions.

14 March 2025 in Allergy
Verified
Journal Article
Open access
NBNadia Baalbaki
Nadia Baalbaki
ESElise Margaretha Adriana Slob
Elise Margaretha Adriana Slob
SKSamuel W. Kazer
Samuel W. Kazer
MAMahmoud I Abdel‐Aziz
Mahmoud I Abdel‐Aziz
HBHarm Jan Bogaard
Harm Jan Bogaard
Anke H. Maitland-van der ZeeAnke H. Maitland-van der Zee
Anke H. Maitland-van der Zee
An estimated 10% of coronavirus disease (COVID‐19) survivors suffer from persisting symptoms referred to as long COVID (LC), a condition for which approved treatment options are still lacking. This systematic review (PROSPERO: CRD42024499281) aimed to explore the pathophysiological mechanisms underlying LC and potential treatable traits across symptom‐based phenotypes. We included studies with primary data, written in English, focusing on omics analyses of human samples from LC patients with persistent symptoms of at least 3 months. Our search in PubMed and Embase, conducted on January 8, 2024, identified 642 studies, of which 29 met the inclusion criteria after full‐text assessment. The risk of bias was evaluated using the Joanna Briggs Institute appraisal tool. The synthesis of omics data, including genomics, transcriptomics, proteomics, metabolomics, and metagenomics, revealed common findings associated with fatigue, cardiovascular, pulmonary, neurological, and gastrointestinal phenotypes. Key findings included mitochondrial dysfunction, dysregulated microRNAs associated with pulmonary dysfunction, tissue impairment, blood–brain barrier disruption, coagulopathy, vascular dysfunction, microbiome disturbances, microbial‐derived metabolite production and persistent inflammation. Limitations include cross‐study heterogeneity and variability in sampling methods. Our review emphasizes the complexity of LC and the need for further longitudinal omics‐integrated studies to advance the development of biomarkers and targeted treatments.